Opko Health (OPK) : Rk Asset Management reduced its stake in Opko Health by 4.14% during the most recent quarter end. The investment management company now holds a total of 884,386 shares of Opko Health which is valued at $8,799,641 after selling 38,231 shares in Opko Health , the firm said in a disclosure report filed with the SEC on Oct 11, 2016.Opko Health makes up approximately 8.04% of Rk Asset Management’s portfolio.
Other Hedge Funds, Including , Fisher Asset Management boosted its stake in OPK in the latest quarter, The investment management firm added 403 additional shares and now holds a total of 38,229 shares of Opko Health which is valued at $380,379. Advisory Services Network added OPK to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $991.Bnp Paribas Arbitrage Sa boosted its stake in OPK in the latest quarter, The investment management firm added 4,468 additional shares and now holds a total of 6,879 shares of Opko Health which is valued at $73,880.Eqis Capital Management reduced its stake in OPK by selling 2,449 shares or 12.75% in the most recent quarter. The Hedge Fund company now holds 16,758 shares of OPK which is valued at $179,981. Opko Health makes up approx 0.01% of Eqis Capital Management’s portfolio.
Opko Health closed down -0.29 points or -2.91% at $9.66 with 27,84,678 shares getting traded on Tuesday. Post opening the session at $9.94, the shares hit an intraday low of $9.57 and an intraday high of $9.99 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Opko Health reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.03. The company had revenue of $357.10 million for the quarter, compared to analysts expectations of $324.11 million. The company’s revenue was up 742.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.